% 0期刊文章% Divyanshu Dubey %一个卡尔Krecke肖恩Pittock % %最后p·莫里斯%一个伊利亚Sechi %一个布莱恩Weinshenker尼古拉斯Zalewski % % Eslam商社%克劳迪娅Lucchinetti %一个詹姆斯·弗莱尔%阿方索s洛佩兹奇%约翰·陈% Jiraporn Jitprapaikulsan %一个Avi Gadoth安德鲁·麦肯% %一个马克Keegan % Jan-Mendelt Tillema %一个马克·帕特森Elie Naddaf % %肯尼斯·泰勒凯文Messacar % % Eoin弗拉纳根% T髓少突细胞糖蛋白自身抗体骨髓炎;临床特点,MRI线索和鉴别器从其他脱髓鞘脊髓炎病因(S21.005) % D J神经病学2019% % P S21.005 % V 92% N 15补充% X目的:评价临床、放射学和预后特点MOG-IgG脊髓炎,比较水通道蛋白4 (AQP4)首页免疫球蛋白和多发性硬化症(MS)脊髓炎。背景:越来越多的证据表明,检测MOG-IgG定义了一个临床综合征不同于女士和AQP4-IgG血清反应阳性的NMOSD。的临床和影像学特征识别MOG-IgG骨髓炎可以早期诊断,从而提高预测和治疗决策。设计/方法:梅奥诊所的病人(2000 - 2017)与骨髓炎和血清阳性MOG-IgG都包括在内。AQP4-IgG脊髓炎(n = 46)和多发性硬化症(MS)脊髓炎(n = 26)患者用作比较。结果变量包括改良Rankin得分(夫人)和步态援助的必要性。MRI特征比较neuro-radiologist蒙蔽的方式。结果:54个MOG-IgG脊髓炎患者包括在内。孤立的横向脊髓炎是29的初始临床表现(53.5%)和10(19%)最初诊断为病毒性/ post-viral急性弛缓性脊髓炎。某些特性有利于MOG-IgG AQP4-IgG或骨髓炎是女士T2-signal异常局限于灰质(矢状线和轴向H-sign)和缺乏增强(p < 0.05)。Longitudinally-extensive t2损伤在MOG-IgG相似的频率和AQP4-IgG脊髓炎(80% vs 79%;p = 0.52),但没有找到女士在一个以上的脊髓损伤和圆锥与MOG-IgG更频繁的参与比AQP4-IgG但没有不同于依赖轮椅女士脊髓炎最低点发生在三分之一的MOG-IgG和AQP4-IgG患者但从未女士然而,复苏与MOG-IgG比AQP4-IgG病人。结论:骨髓炎MOG-IgG相关疾病的早期表现,可能有急性弛缓性骨髓炎的临床表型。 We identified clinical and MRI attributes that give a clue to MOG-IgG myelitis and help distinguish it from AQP4-IgG and MS myelitis.Disclosure: Dr. Dubey has nothing to disclose. Dr. Pittock receives research support from Alexion Pharmaceuticals, Medimmune, and Grifols. Dr. Krecke has nothing to disclose. Dr. Morris has nothing to disclose. Dr. Sechi has nothing to disclose. Dr. Zalewski has nothing to disclose. Dr. Weinshenker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Alexion, MedImmune, Caladrius Biosciences, Brainstorm Therapeutics, Chugai, and Roivant Sciences. Dr. Weinshenker has received royalty, license fees, or contractual rights payments from RSR Ltd, Oxford University, Hospices Civil de Lyon, MVZ Labor PD Dr. Volkmann und Kollegen GbR. Dr. Shosha has nothing to disclose. Dr. Lucchinetti has nothing to disclose. Dr. Fryer has nothing to disclose. Dr. Lopez has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Jitprapaikulsan has nothing to disclose. Dr. McKeon has received research support from Medimmune, Euroimmun, Grifols and Alexion. Dr. Gadoth has nothing to disclose. Dr. Keegan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cambridge University Press. Dr. Keegan has received research support from Biogen. Dr. Tillema has nothing to disclose. Dr. Naddaf has nothing to disclose. Dr. Patterson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Amicus, Intrabio, Orphazyme, and Vtesse. Dr. Patterson has received personal compensation in an editorial capacity for Sage, the Society for the Study of Inborn Errors of Metabolism, and Up-To-Date. Dr. Patterson has received research support from Actelion and Orphazyme. Dr. Messacar has received research support from Dr. Messacar receives grant support from the NIH. Dr. Tyler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with DNAtrix Therapeutics. Dr. Tyler has received research support from Taiga Biotechnologies Inc. Dr. Flanagan has received research support from Medimmune. %U